机构：[1]Department of Pharmacy, Xuanwu Hospital, Capital Medical University, Beijing, China首都医科大学宣武医院[2]Renal Division, Peking University First Hospital, Peking University, Beijing, China[3]Department of Pharmacy, The Second Hospital of Jilin University, Changchun, China[4]Department of Pharmacy, 900 Hospital of the Joint Logistic Team, Fuzhou, China[5]Department of Pharmacy, Sichuan Provincial People’s Hospital, Chengdu, China四川省人民医院[6]Department of Pharmacy, Affiliated Tumor Hospital Harbin Medical University, Harbin, China[7]Department of Pharmacy, Nanjing Drum Tower Hospital, Nanjing, China[8]Department of Pharmacy, Beijing Tongren Hospital, Beijing, China首都医科大学附属同仁医院[9]Department of Pharmacy, Qinghai University Affiliated Hospital, Xining, China[10]Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China[11]Department of Pharmacy, The First Hospital Affiliated to Army Medical University, Chongqing, China[12]Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, China中国医科大学盛京医院[13]Department of Pharmacy, Peking University Shougang Hospital, Beijing, China[14]Department of Pharmacy, Guizhou Provincial People’s Hospital, Guiyang, China[15]Department of Pharmacy, Tianjin First Center Hospital, Tianjin, China[16]Department of Pharmacy, Henan Provincial Peoples’ Hospital, Zhengzhou, China[17]Department of Pharmacy, Shandong Provincial Qianfoshan Hospital, Jinan, China[18]Department of Pharmacy, The Second Hospital of Nanchang University, Nanchang, China[19]Department of Pharmacy, The Tongji Affiliated Hospital of Tongji Medical College, Huazhong University of science, Wuhan, China[20]Department of Pharmacy, Anhui Provincial Hospital, Hefei, China[21]Department of Pharmacy, Beijing Anzhen Hospital, Beijing, China首都医科大学附属安贞医院[22]Department of Pharmacy, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China[23]Department of Pharmacy, First Affiliated Hospital of Chongqing Medical University, Chongqing, China重庆医科大学附属第一医院[24]Department of Pharmacy, Peking University People’s Hospital, Beijing, China
Introduction: Drug-induced acute kidney injury (D-AKI) is one of the important types of AKI. The incidence of D-AKI in China has rarely been studied. Objective: This study aims to explore the disease burden, related drugs, and risk factors of D-AKI. Methods: A nationwide cross-sectional survey was conducted in adult patients from 23 academic hospitals in 17 provinces in China. Suspected AKI was screened based on serum creatinine changes in accordance with the 2012 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for AKI, patients who met the diagnosis of hospital-acquired AKI in January and July of 2014 were defined. Suspected AKI was firstly evaluated for the possibility of D-AKI by pharmacists using the Naranjo Scale and finally defined as D-AKI by nephrologists through reviewing AKI clinical features. Results: Altogether 280,255 hospitalized patients were screened and 1,960 cases were diagnosed as hospital-acquired AKI, among which 735 cases were defined as having D-AKI (37.50%, 735/1,960) with an in-hospital mortality rate of 13.88% and 54.34% of the survivors did not achieve full renal recovery. 1,642 drugs were related to AKI in these patients. Anti-infectives, diuretics, and proton pump inhibitors were the top 3 types of drugs relevant to D-AKI, accounting for 66.63% cumulatively. Besides age, AKI staging, severe disease, hypoalbuminemia, plasma substitute, and carbapenem related D-AKI were independent risk factors for in-hospital mortality of D-AKI patients. Conclusion: In China, D-AKI has caused a substantial medical burden. Efforts should be made to pursue nephrotoxic drug stewardship to minimize attributable risk and improve the prevention, diagnosis, and treatment of D-AKI.
基金：
Medical Policy and Administration
Department, National Health and Family Planning Commission
of China, 2015; the National Natural Science Foundation
of China (Nos. 91742205 and 81625004); the Beijing Young Scientist
Program (BJJWZYJH01201910001006); and Peking University
Clinical Scientist Program by the Fundamental Research
Funds for the Central Universities.
第一作者机构：[1]Department of Pharmacy, Xuanwu Hospital, Capital Medical University, Beijing, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Pharmacy, Xuanwu Hospital, Capital Medical University, Beijing, China[2]Renal Division, Peking University First Hospital, Peking University, Beijing, China[*1]Renal Division Peking University First Hospital, Peking University No. 8 Xishiku Street, Xicheng District, Beijing 100034 (China)[*2]Department of Pharmacy, Xuanwu Hospital, Capital Medical University No. 45 Changchun Street, Xicheng District Beijing 100053 (China)
推荐引用方式(GB/T 7714)：
Liu Chen,Yan Suying,Wang Yuqin,et al.Drug-Induced Hospital-Acquired Acute Kidney Injury in China: A Multicenter Cross-Sectional Survey[J].KIDNEY DISEASES.2021,7(2):143-155.doi:10.1159/000510455.
APA：
Liu, Chen,Yan, Suying,Wang, Yuqin,Wang, Jinwei,Fu, Xiujuan...&Yang, Li.(2021).Drug-Induced Hospital-Acquired Acute Kidney Injury in China: A Multicenter Cross-Sectional Survey.KIDNEY DISEASES,7,(2)
MLA：
Liu, Chen,et al."Drug-Induced Hospital-Acquired Acute Kidney Injury in China: A Multicenter Cross-Sectional Survey".KIDNEY DISEASES 7..2(2021):143-155
